Albumin market seen reaching $8.95 billion by 2030

Allied Market Research projects the global albumin market will grow from $4.81 billion in 2020 to $8.95 billion by 2030, driven by expanding non-therapeutic use, plasma collection and immunoglobulin production. The report also points to North America as the largest market in 2022 and Asia-Pacific as the fastest-growing region through 2030.

Why it matters: - Albumin is used in treatments tied to fluid resuscitation, wound healing and hypoalbuminemia, so demand reflects broader activity in hospitals, surgery and plasma-based care. - The market outlook points to continued growth in both therapeutic and non-therapeutic uses, which could shape investment, manufacturing and supply decisions across the plasma and biopharma sectors.

What happened: - Allied Market Research published a report on the global albumin market that valued it at $4.81 billion in 2020. - The report forecasts the market will reach $8.95 billion by 2030, implying a 6.4% compound annual growth rate from 2021 to 2030. - The study covers market dynamics, major segments, value chain, competition and regional trends. - The report is available through a sample PDF request and a purchase inquiry page.

The details: - Albumin is the most abundant protein in blood plasma and makes up about 50% of total blood protein. - Albumin helps maintain oncotic blood pressure and transports hormones, fatty acids and other compounds. - The product is derived from blood plasma through fractionation. - The report includes human serum albumin, bovine serum albumin and recombinant albumin. - Drivers cited in the report include rising non-therapeutic use of albumin, higher immunoglobulin production, increased plasma collection and growth in plant-based albumin development. - Regulatory restrictions on albumin products are identified as a restraint. - Rising cancer surgeries, which can lead to hypoalbuminemia, are identified as a growth opportunity. - The human serum albumin segment led the market in 2022 and represented almost two-thirds of global revenue. - Human serum albumin is projected to post the fastest segment growth at a 6.5% CAGR through 2030. - The therapeutics segment held about two-fifths of the market in 2022 and is projected to grow at a 6.7% CAGR. - The B2B sales channel accounted for almost three-fifths of the market in 2022. - The B2C channel is projected to grow at a 6.7% CAGR through 2030. - North America held more than two-fifths of global revenue in 2022. - Asia-Pacific is projected to post the fastest regional growth at a 7.0% CAGR through 2030. - The report lists Takeda Pharmaceuticals, Thermo Fisher Scientific, Ventria Bioscience, Baxter International, China Biologic Products, Merck KGaA, Novozymes, Octapharma, CSL Limited and Grifols among the top companies.

Between the lines: - The forecast suggests albumin demand is being pulled by both clinical use and industrial-scale plasma processing, not just one medical niche. - The fastest growth in Asia-Pacific points to a regional shift tied to healthcare infrastructure expansion and more surgical procedures. - The B2B lead in sales shows the market still depends heavily on institutional and manufacturing buyers rather than direct consumer demand.

What’s next: - The report expects human serum albumin and therapeutics to remain the dominant categories through the forecast period. - Asia-Pacific is expected to narrow the gap with mature markets as healthcare access, awareness and surgical volumes rise. - Companies in the market are likely to keep focusing on plasma supply, partnerships and product development as demand expands.

The bottom line: - Albumin remains a specialized but growing global market, with the strongest upside coming from therapeutic use, plasma supply chains and faster growth in Asia-Pacific.